176 related articles for article (PubMed ID: 35110641)
21. HIV treatment strategies across Central, Eastern and Southeastern Europe: New times, old problems.
Papadopoulos A; Thomas K; Protopapas K; Antonyak S; Begovac J; Dragovic G; Gökengin D; Aimla K; Krasniqi V; Lakatos B; Mardarescu M; Matulionyte R; Mulabdic V; Oprea C; Panteleev A; Sedláček D; Sojak L; Skrzat-Klapaczyńska A; Vassilenko A; Yancheva N; Yurin O; Horban A; Kowalska JD;
HIV Med; 2023 Apr; 24(4):462-470. PubMed ID: 36196025
[TBL] [Abstract][Full Text] [Related]
22. Comorbidities and co-medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan.
Naito T; Suzuki M; Fukushima S; Yuda M; Fukui N; Tsukamoto S; Fujibayashi K; Goto-Hirano K; Kuwatsuru R
HIV Med; 2022 May; 23(5):485-493. PubMed ID: 34821006
[TBL] [Abstract][Full Text] [Related]
23. Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria.
Ndembi N; Murtala-Ibrahim F; Tola M; Jumare J; Aliyu A; Alabi P; Mensah C; Abimiku A; Quiñones-Mateu ME; Crowell TA; Rhee SY; Shafer RW; Gupta R; Blattner W; Charurat ME; Dakum P
AIDS Res Ther; 2020 Nov; 17(1):64. PubMed ID: 33143751
[TBL] [Abstract][Full Text] [Related]
24. Genotyping and outcomes of presumptive second line ART failure cases switched to third line or maintained on second line ART in Mumbai, India.
Gill N; Van den Bergh R; Wut Yee Kyaw K; Laxmeshwar C; Das M; Rastogi S; Arago Galindo M; Mansoor H; Kalon S; Isaakidis P
PLoS One; 2019; 14(11):e0225631. PubMed ID: 31751433
[TBL] [Abstract][Full Text] [Related]
25. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
[TBL] [Abstract][Full Text] [Related]
27. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens.
Maggi P; Ricci ED; Cicalini S; Pellicanò GF; Celesia BM; Vichi F; Cascio A; Sarchi E; Orofino G; Squillace N; Madeddu G; De Socio GV; Bargiacchi O; Molteni C; Masiello A; Saracino A; Menzaghi B; Falasca K; Taramasso L; Di Biagio A; Bonfanti P
BMC Infect Dis; 2023 Apr; 23(1):227. PubMed ID: 37059996
[TBL] [Abstract][Full Text] [Related]
28. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
29. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study.
Corti N; Menzaghi B; Orofino G; Guastavigna M; Lagi F; Di Biagio A; Taramasso L; De Socio GV; Molteni C; Madeddu G; Salomoni E; Pellicanò GF; Pontali E; Bellagamba R; Celesia BM; Cascio A; Sarchi E; Gulminetti R; Calza L; Maggi P; Cenderello G; Bandera A; Carleo MA; Falasca K; Ferrara S; Martini S; Guadagnino G; Angioni G; Bargiacchi O; Ricci ED; Squillace N; Bonfanti P
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675955
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
[TBL] [Abstract][Full Text] [Related]
31. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
32. High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.
Mboumba Bouassa RS; Mossoro-Kpinde CD; Gody JC; Veyer D; Péré H; Matta M; Robin L; Grésenguet G; Charpentier C; Bélec L
J Antimicrob Chemother; 2019 Jul; 74(7):2030-2038. PubMed ID: 30891603
[TBL] [Abstract][Full Text] [Related]
33. Integrase inhibitor-based regimens are related to favorable systemic inflammatory index and platecrit scores in people living with HIV (PLWH) up to 2 years.
Şahin EA; Mavi D; Kara E; Sönmezer MÇ; İnkaya AÇ; Ünal S
Postgrad Med; 2022 Aug; 134(6):635-640. PubMed ID: 35671079
[TBL] [Abstract][Full Text] [Related]
34. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy.
Pasternak AO; Vroom J; Kootstra NA; Wit FW; de Bruin M; De Francesco D; Bakker M; Sabin CA; Winston A; Prins JM; Reiss P; Berkhout B;
Elife; 2021 Aug; 10():. PubMed ID: 34387543
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Integrase Strand Transfer Inhibitors (INSTIs) and Protease-Boosted Inhibitors (PIs) on the Reduction in Chronic Immune Activation in a Virally Suppressed, Mainly Male Population Living with HIV (PLWH).
Nitsotolis T; Kyriakoulis KG; Kollias A; Papalexandrou A; Kalampoka H; Mastrogianni E; Basoulis D; Psichogiou M
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399618
[No Abstract] [Full Text] [Related]
36. Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.
Neesgaard B; Mocroft A; Zangerle R; Wit F; Lampe F; Günthard HF; Necsoi C; Law M; Mussini C; Castagna A; Monforte AD; Pradier C; Chkhartisvilli N; Reyes-Uruena J; Vehreschild JJ; Wasmuth JC; Sönnerborg A; Stephan C; Greenberg L; Llibre JM; Volny-Anne A; Peters L; Pelchen-Matthews A; Vannappagari V; Gallant J; Rieger A; Youle M; Braun D; De Wit S; Petoumenos K; Borghi V; Spagnuolo V; Tsertsvadze T; Lundgren J; Ryom L;
PLoS One; 2020; 15(12):e0243625. PubMed ID: 33382756
[TBL] [Abstract][Full Text] [Related]
37. Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany.
Lopes S; O'Day K; Meyer K; Van Stiphout J; Punekar Y; Radford M; Haas JS
Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):270-278. PubMed ID: 31950545
[TBL] [Abstract][Full Text] [Related]
38. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC
Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695
[TBL] [Abstract][Full Text] [Related]
40. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).
; Berenguer J; Polo R; Aldeguer JL; Lozano F; Aguirrebengoa K; Arribas JR; Blanco JR; Boix V; Casado JL; Clotet B; Crespo M; Domingo P; Estrada V; García F; Gatell JM; González-García J; Gutiérrez F; Iribarren JA; Knobel H; Llibre JM; Locutura J; López JC; Miró JM; Moreno S; Podzamczer D; Portilla J; Pulido F; Ribera E; Riera M; Rubio R; Santos J; Sanz-Moreno J; Sanz J; Téllez MJ; Tuset M; Rivero A
Enferm Infecc Microbiol Clin; 2015 Oct; 33(8):544-56. PubMed ID: 26021186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
